

SUPPLEMENTARY TABLES

Supplementary Table 1. Cancer-Directed Treatments Received Before Metastatic SCCHN Diagnosis^a

Cancer-Directed Treatment	n = 105 (47.7%)	%
Number (%) of patients		
Surgery only	14	13.3
Radiotherapy only	5	4.8
Radiotherapy preoperative	6	5.7
Radiotherapy postoperative	48	45.7
Systemic chemotherapy only	0	0.0
Systemic chemotherapy preoperative (neoadjuvant or induction)	15	14.3
Systemic chemotherapy postoperative without clinically evident residual disease (adjuvant)	16	15.2
Systemic chemotherapy postoperative for residual disease	3	2.9
Systemic chemotherapy concurrent with radiotherapy	27	25.7
Radiotherapy followed by chemotherapy	13	12.4
Chemotherapy followed by radiotherapy	23	21.9
Not reported	3	2.9

SCCHN = squamous cell carcinoma of the head and neck.

Note: Totals may sum to more than 100% because respondents were able to provide multiple answers.

^a Patients initially diagnosed with stage I through stage IVB disease.

Supplementary Table 2. Chemotherapy and Targeted Therapy Agents Used to Treat Metastatic SCCHN, by Therapy Line

Specific Chemotherapy and Targeted Therapy Agents	First Line		Second Line		Third Line		Fourth Line	
	N	%	N	%	N	%	N	%
Number (%) of patients receiving each treatment	220	100.0	220	100.0	220	100.0	4	1.8
Single agents								
Capecitabine	—	—	—	—	6	2.7	1	25.0
Carboplatin	—	—	4	1.8	10	4.6	—	—
Cetuximab	—	—	19	8.6	43	19.6	—	—
Cisplatin	8	3.6	6	2.7	—	—	—	—
Docetaxel	—	—	99	45.0	40	18.2	1	25.0
Gemcitabine	—	—	6	2.7	27	12.3	1	25.0
Lapatinib	—	—	—	—	1	0.5	—	—
Methotrexate	—	—	1	0.5	43	19.6	—	—
Paclitaxel	—	—	28	12.7	16	7.3	—	—
Vinorelbine	—	—	2	0.9	4	1.8	—	—
Combination therapy (two agents)								
Capecitabine + carboplatin	2	0.9	1	0.5	—	—	—	—
Capecitabine + cisplatin	10	4.5	1	0.5	—	—	—	—
Capecitabine + lapatinib	—	—	—	—	1	0.5	—	—
Carboplatin + cetuximab	—	—	3	1.4	2	0.9	—	—

Specific Chemotherapy and Targeted Therapy Agents	First Line		Second Line		Third Line		Fourth Line	
	N	%	N	%	N	%	N	%
Carboplatin + docetaxel	—	—	1	0.5	—	—	—	—
Carboplatin + etoposide	—	—	—	—	—	—	1	25.0
Carboplatin + 5-FU	26	11.8	2	0.9	2	0.9	—	—
Carboplatin + gemcitabine	9	4.1	2	0.9	4	1.8	—	—
Carboplatin + paclitaxel	11	5.0	19	8.6	3	1.4	—	—
Cetuximab + cisplatin	—	—	4	1.8	—	—	—	—
Cetuximab + docetaxel	—	—	1	0.5	—	—	—	—
Cetuximab + 5-FU	—	—	1	0.5	—	—	—	—
Cetuximab + paclitaxel	—	—	1	0.5	—	—	—	—
Cisplatin + docetaxel	2	0.9	5	2.3	—	—	—	—
Cisplatin + 5-FU	102	46.4	3	1.4	4	1.8	—	—
Cisplatin + gemcitabine	4	1.8	—	—	—	—	—	—
5-FU + gemcitabine	—	—	1	0.5	1	0.5	—	—
5-FU + paclitaxel	—	—	—	—	1	0.5	—	—
Gemcitabine + vinorelbine	—	—	5	2.3	10	4.6	—	—
Combination therapy (three agents)								
Capecitabine + cetuximab + cisplatin	1	0.5	—	—	—	—	—	—
Capecitabine + cisplatin + epirubicin	—	—	—	—	1	0.5	—	—
Carboplatin + cetuximab + 5-FU	3	1.4	4	1.8	1	0.5	—	—
Carboplatin + cetuximab + paclitaxel	1	0.5	1	0.5	—	—	—	—

Specific Chemotherapy and Targeted Therapy Agents	First Line		Second Line		Third Line		Fourth Line	
	N	%	N	%	N	%	N	%
Cetuximab + cisplatin + 5-FU	36	16.4	—	—	—	—	—	—
Cisplatin + docetaxel + 5-FU	3	1.4	—	—	—	—	—	—
Cisplatin + 5-FU + paclitaxel	2	0.9	—	—	—	—	—	—
Not reported	—	—	—	—	—	—	—	—

5-FU = 5-fluorouracil; SCCHN = squamous cell carcinoma of the head and neck. "Paclitaxel" refers to the non-protein-bound form of the drug.